25 March 2021 - coronavirus update
The group has announced that the Virolens rapid COVID-19 screening device, for which it is the exclusive manufacturing partner, is close to being approved for sale in the UK. Although revenues to TT will depend on the success of iAbra, its marketing partner, converting expressions of interest into firm orders, this is clearly a positive for the group. The share price has spiked up on the news and we would expect this to drift back in the short-term although long-term prospects for the group remain sound. The shares remain a BUY . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
